Serge Saxonov - Oct 5, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Executive Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Oct 5, 2021
Transactions value $
-$2,086,521
Form type
4
Date filed
10/7/2021, 04:15 PM
Previous filing
Sep 9, 2021
Next filing
Nov 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $26.2K +5.21K +0.58% $5.04* 904K Oct 5, 2021 Direct F1
transaction TXG Class A Common Stock Options Exercise $39.7K +3.46K +0.38% $11.48 907K Oct 5, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$716K -5.02K -0.55% $142.47 902K Oct 5, 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale -$868K -6.06K -0.67% $143.40 896K Oct 5, 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale -$274K -1.9K -0.21% $144.40 894K Oct 5, 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale -$250K -1.72K -0.19% $145.42 892K Oct 5, 2021 Direct F1, F5
transaction TXG Class A Common Stock Sale -$43.8K -300 -0.03% $146.12 892K Oct 5, 2021 Direct F1, F6
holding TXG Class A Common Stock 4.5K Oct 5, 2021 See footnote F7
holding TXG Class A Common Stock 90K Oct 5, 2021 See footnote F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -5.21K -7.55% $0.00 63.7K Oct 5, 2021 Class A Common Stock 5.21K $5.04 Direct F1, F9
transaction TXG Stock Option (right to buy) Options Exercise $0 -3.46K -5.95% $0.00 54.7K Oct 5, 2021 Class A Common Stock 3.46K $11.48 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $141.94 to $142.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $142.96 to $143.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $143.96 to $144.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $144.96 to $145.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $146.02 to $146.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9 This option, originally for 250,000 shares, of which 186,260 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F10 This option, originally for 145,786 shares, of which 91,116 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.